Traders should monitor upcoming clinical trial updates, particularly efficacy signals in later cohorts. A successful trial could lead to accelerated development, partnerships, or licensing deals. Given the company's $1M market cap, any positive data could lead to significant stock price movement.
Price Chart
Executive Summary
Clearmind Medicine announced that its independent Data and Safety Monitoring Board (DSMB) issued a positive recommendation to continue the ongoing Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD), based on favorable safety data from the third cohort with no serious adverse events reported. The trial will now proceed to the fourth cohort with an increased dose of 160mg.
Key Facts
- Independent Data and Safety Monitoring Board (DSMB) issued a positive recommendation to continue the Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD).
- The recommendation follows successful completion of the third cohort with no serious adverse events reported.
- CMND-100 was well tolerated, reinforcing its favorable safety and tolerability profile.
- The trial will proceed to the fourth cohort with an increased dose of 160mg.
- The Phase I/IIa trial is FDA-approved, multinational, and multicenter, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100.
Financial Impact
No direct financial figures disclosed, but positive clinical trial progress significantly de-risks development and increases potential for future funding, partnerships, or regulatory milestones.
Risk Factors
- Clinical trials carry inherent risk of failure in later stages despite positive safety data.
- Small market cap ($1M) indicates high volatility and potential liquidity risk.
- Forward-looking statements are subject to risks and uncertainties, including regulatory, development, and financing risks detailed in prior SEC filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-043826 |
| Document: ea028645501ex99-1.htm | 0001213900-26-043826 |
| Document: 0001213900-26-043826-index-headers.html | 0001213900-26-043826 |
| Document: 0001213900-26-043826-index.html | 0001213900-26-043826 |
| Document: 0001213900-26-043826.txt | 0001213900-26-043826 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.12 (+3.40%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.12 (−5.83%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers